Insilico and Qilu partner to create generative AI cardiometabolic drugs
Insilico Medicine and Qilu Pharmaceutical Group are expanding their existing R&D collaboration to apply generative AI to cardiometabolic drug discovery.
List view / Grid view
Insilico Medicine and Qilu Pharmaceutical Group are expanding their existing R&D collaboration to apply generative AI to cardiometabolic drug discovery.
Insilico Medicine and Servier have announced a multi-year collaboration to accelerate the discovery of new cancer therapies, using artificial intelligence to tackle challenging oncology targets and shorten early-stage drug development timelines.
Insilico Medicine has partnered with TaiGen Biotechnology to exclusively license its AI-designed PHD inhibitor, ISM4808, for the treatment of CKD-related anaemia in Greater China.
Insilico Medicine has announced ISM3830, an AI-designed CBLB inhibitor that has demonstrated promising preclinical results.
Researchers have identified idiopathic pulmonary fibrosis (IPF) as a powerful model for exploring treatments that target the biology of ageing.
Scientists have used AI to design a molecule that disrupts a key protein interaction driving up to 70 percent of cancers - once thought impossible to drug.
Insilico Medicine’s AI-designed drug for idiopathic pulmonary fibrosis (IPF), Rentosertib, has been granted an official name by USAN. This is the first drug where both the target and compound were discovered using generative AI, marking a major milestone in AI-driven drug development.
Insilico Medicine’s AI-designed CDK12/13 inhibitors show promise against treatment-resistant cancers. Find out how this breakthrough could reshape cancer therapy.
Insilico Medicine’s AI-designed drug ISM5939 has received FDA IND clearance for treating solid tumours. By targeting ENPP1, it enhances anti-tumour immunity and is set to begin Phase I trials soon.
Amidst the transformative era of AI in drug discovery, this report focuses on recent advancements, notably the development of highly accurate drug target models, and how AI is revolutionising precision in identifying drug targets.
Insilico Medicine has announced the nomination of ISM6331 as a potential best-in-class pan-TEAD inhibitor for the treatment of advanced solid tumours.
Drug Target Review rounds up the latest updates on research into coronavirus treatments, focusing on virtual screening to find therapies for COVID-19.
Researchers have developed a new AI system which was able to discover and then successfully test several new compounds within 46 days.